HHC
DCPH

Hutchin Hill Capital’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Hutchin Hill Capital’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-27,915
Closed -$530K – 752
2017
Q3 		$530K Buy
+27,915
New +$511K 0.02% 519

Other funds holding DCPH

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Hutchin Hill Capital's DCPH Position: Q4 2017 in Review

Hutchin Hill Capital sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q4 2017, closing a stake of 27,915 shares — an estimated $530K sold.

Hutchin Hill Capital first reported a position in DCPH in Q3 2017 and held it in 1 quarter. The position peaked at $530K in Q3 2017. 59 funds tracked by Wall St. Rank hold DCPH as of Q4 2017.

  • Hutchin Hill Capital reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 27,915 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q4 2017, an estimated $530K.
  • Hutchin Hill Capital first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Hutchin Hill Capital's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $530K in Q3 2017.
  • 59 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q4 2017.

Based on Hutchin Hill Capital's 13F filing for Q4 2017, filed 12 Feb 2018.